CURE’s neuroendocrine cancer page features the latest cancer news and updates on neuroendocrine cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in neuroendocrine cancer.
April 27th 2022
Before being diagnosed with neuroendocrine cancer, I started to live a healthier life and took notice of some concerning symptoms.
March 24th 2022
The Food and Drug Administration plans on reviewing multiple new cancer therapies this spring.
March 3rd 2022
When I was first diagnosed with a stage 4 neuroendocrine tumor in my small intestine, I went through three stages of coping with my cancer: anger, planning and living life.
January 5th 2022
The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.
December 13th 2021
For patients with neuroendocrine tumors that have spread, curating a liver-directed approach may make their treatment process less risky and less invasive, according to an expert.
December 1st 2021
Catching tumors through imaging at an early stage can help guide treatment decisions and may improve a patient’s quality of life — which is why it’s important for patients to stay educated on their options.
September 24th 2021
It is vital to find support when your child has cancer. In this two-part episode of the “CURE® Talks Cancer” podcast, a family shares how they were able to remain strong as their 9-year-old was treated for neuroendocrine cancer.
September 23rd 2021
Where do you turn when your child is diagnosed with a rare cancer? In this two-part episode of the “CURE® Talks Cancer” podcast, a family shares the harrowing experience of learning their nine-year-old had neuroendocrine cancer.
January 20th 2021
The combination of Inlyta (axitinib) and the synthetic hormone octreotide acetate failed to significantly improve progression-free survival, compared to placebo with the synthetic hormone. However, the results indicated the Inlyta-based combination did improve disease response in patients versus the placebo-based combination.
August 26th 2020
Often uncovered by accident, appendiceal cancers trigger few symptoms until they’re advanced and can be difficult to detect and treat.
May 1st 2020
From a renowned actor passing away after a rare neuroendocrine cancer diagnosis and years of treatment to LUNGevity announcing a new fund for patients with lung cancer in need of financial assistance during the COVID-19 pandemic, here’s what’s happening in the cancer space this week.
April 14th 2020
COVID-19 has forced many people into a “new normal” that they aren’t familiar with and may not be equipped to handle. But cancer survivors are more prepared than most to handle the ramifications of the pandemic.
September 27th 2019
Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) led to a 44% response rate in patients with high-grade neuroendocrine tumors, according to phase 2 study findings.
August 23rd 2019
From celebrity news to a new partnership aimed to help patients and their caregivers, here’s what is making headlines in the cancer space this week.
June 15th 2019
This essay was written by Tracey M. Hopkins nominating registered nurse Rubirosa Ison, St. Joseph’s Hospital-North, Lutz, Florida, for CURE®’s 2019 Extraordinary Healer® Award.
October 12th 2017
Before I was diagnosed, I had my share of illnesses, but none that slowed me down like cancer could.